World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
98
Citations
38005
World Ranking
785
National Ranking
442

Medicine

D-Index
98
Citations
38062
World Ranking
8882
National Ranking
4574

David A. Scheinberg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David A. Scheinberg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 448 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David A. Scheinberg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David A. Scheinberg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 98 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

David A. Scheinberg is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research spans several fields including Medicine, Biochemistry, Genetics and Molecular Biology, with a significant focus on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Genetics.

The scientist's primary research topics include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • Vaccines and immunoinformatics approaches
  • Virus-based gene therapy research
  • Nanowire Synthesis and Applications

Frequent publication venues for their work include:

  • Blood
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Immunology Research
  • Cancer Research
  • Clinical Lymphoma Myeloma & Leukemia

Selected recent papers authored by or involving David A. Scheinberg are:

  • "Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma," 2020, Cancer Discovery
  • "Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA," 2022, Nature Medicine
  • "Banning carbon nanotubes would be scientifically unjustified and damaging to innovation," 2020, Nature Nanotechnology
  • "Engineering CAR-T cells to activate small-molecule drugs in situ," 2021, Nature Chemical Biology
  • "Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses," 2020, Theranostics

Frequent collaborators in their research include Tao Dao, Martin G. Klatt, Sung Soo Mun, Christopher M. Bourne, and Megan M. Dacek. These co-authors have contributed to multiple publications with David A. Scheinberg.

David A. Scheinberg has been recognized with awards such as membership in the Association of American Physicians, reflecting their involvement in the medical research community.

Best Publications

  • Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

    Raymond P. Warrell;Stanley R. Frankel;Wilson H. Miller;David A. Scheinberg

  • Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

    Steven L. Soignet;Peter Maslak;Zhu-Gang Wang;Suresh Jhanwar

  • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

    Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila

  • Central challenges facing the national clinical research enterprise.

    Nancy S. Sung;William F. Crowley;Myron Genel;Patricia Salber

  • United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

    Steven L. Soignet;Stanley R. Frankel;Dan Douer;Martin S. Tallman

  • Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

    Yasin Şenbabaoğlu;Ron S. Gejman;Ron S. Gejman;Andrew G. Winer;Ming Liu

  • Increasing antibody affinity by altering glycosylation of immunoglobulin variable region

    Man Sung Co;David A. Scheinberg;Cary L. Queen

  • Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

    Josephia Muindi;Stanley R. Frankel;Wilson H. Miller;Ann Jakubowski

  • Tumor Therapy with Targeted Atomic Nanogenerators

    Michael R. McDevitt;Dangshe Ma;Lawrence T. Lai;Jim Simon

  • Targeted α particle immunotherapy for myeloid leukemia

    Joseph G. Jurcic;Steven M. Larson;Steven M. Larson;George Sgouros;George Sgouros;Michael R. McDevitt;Michael R. McDevitt

  • Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes

    Michael R. McDevitt;Debjit Chattopadhyay;Barry J. Kappel;Jaspreet Singh Jaggi

  • Radioimmunotherapy with alpha-emitting nuclides

    Michael R. McDevitt;George Sgouros;Ronald D. Finn;John L. Humm

  • Acute myeloid leukaemia.

    Asim Khwaja;Magnus Bjorkholm;Rosemary E Gale;Ross L Levine

  • Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization

    Daniel J. Nolan;Daniel J. Nolan;Alessia Ciarrocchi;Albert Sleiman Mellick;Jaspreet S. Jaggi

  • Paradoxical glomerular filtration of carbon nanotubes

    Alessandro Ruggiero;Carlos H. Villa;Evan Bander;Diego A. Rey

  • Engineered humanized dimeric forms of IgG are more effective antibodies.

    P. C. Caron;W. Laird;Man Sung Co;N. M. Avdalovic

  • Specific human cellular immunity to bcr-abl oncogene-derived peptides

    Monica Bocchia;Tatyana Korontsvit;Qin Xu;Stephen Mackinnon

  • Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid

    Linda Vahdat;Peter Maslak;Wilson H. Miller;Anna Eardley

  • Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.

    Papandreou Cn;Usmani B;Geng Y;Bogenrieder T

  • Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

    J. Pinilla-Ibarz;K. Cathcart;T. Korontsvit;S. Soignet

  • Monoclonal antibody therapy for cancer.

    Lovett Dr;Scheinberg Da;Houghton An

  • Additional file 1: Figures S1â S25. of Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

    Yasin ĹenbabaoÄlu;Ron Gejman;Andrew Winer;Ming Liu

Frequent Co-Authors

George Sgouros
George Sgouros Johns Hopkins University
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center
Andrew M. Scott
Andrew M. Scott La Trobe University
Renier J. Brentjens
Renier J. Brentjens Roswell Park Cancer Institute
Mette Strand
Mette Strand Johns Hopkins University School of Medicine
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center
Richard J. O'Reilly
Richard J. O'Reilly Memorial Sloan Kettering Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Bayard D. Clarkson
Bayard D. Clarkson Memorial Sloan Kettering Cancer Center
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology but considering broader healthcare roles, several related online degrees offer accessible pathways. Many students seek the best easiest LPN programs to get into, which provide foundational nursing skills and a quicker route into patient care. These programs are ideal for hands-on learners looking to enter healthcare efficiently.

Advancing beyond an LPN, aspiring nurse practitioners often look for the what is the easiest NP program to balance quality education with manageable course demands. Choosing the right NP program can impact both career progression and work-life balance, especially for working professionals.

In mental health nursing, specialized credentials are crucial. The best psychiatric mental health nurse practitioner programs online offer strong clinical placement support, a key factor for gaining practical experience and licensure success.

Cost is another important consideration. Many students prioritize affordability when selecting programs, and the cheapest psych NP programs provide valuable options without compromising essential training, making higher education more accessible.

Best Scientists Citing David A. Scheinberg

Trending Scientists

Recently Published Articles